Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Inflammatory Bowel Diseases

  Free Subscription


09.10.2023

4 Aliment Pharmacol Ther
3 Am J Gastroenterol
1 BMC Gastroenterol
3 Dig Dis Sci
2 Gastroenterol Hepatol
8 Inflamm Bowel Dis
3 J Crohns Colitis
1 Mediators Inflamm


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
    Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
    Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
    PubMed         Abstract available

  2. WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
    Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
    Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
    PubMed         Abstract available

  3. FAQERAH N, Walker D, Gerasimidis K
    Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
    PubMed         Abstract available

  4. ARULJOTHY A, Singh S, Narula N, Moran GW, et al
    Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
    Aliment Pharmacol Ther. 2023;58:740-762.
    PubMed         Abstract available


    Am J Gastroenterol

  5. SHUJA A
    Continuing Medical Education Questions: October 2023.
    Am J Gastroenterol. 2023;118:1742.
    PubMed         Abstract available

  6. DEBRUYN JC, Huynh HQ, Griffiths AM, Jacobson K, et al
    ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY.
    Am J Gastroenterol. 2023 Oct 3. doi: 10.14309/ajg.0000000000002552.
    PubMed         Abstract available

  7. COELHO-PRABHU N, Lewis JD
    Update on Endoscopic Dysplasia Surveillance in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023;118:1748-1755.
    PubMed         Abstract available


    BMC Gastroenterol

  8. BURAN T, Batir MB, Cam FS, Kasap E, et al
    Molecular analyses of ADAMTS-1, -4, -5, and IL-17 a cytokine relationship in patients with ulcerative colitis.
    BMC Gastroenterol. 2023;23:345.
    PubMed         Abstract available


    Dig Dis Sci

  9. MCCURDY JD, Chen JH, Golden S, Kukaswadia A, et al
    Perianal Fistulas Are Associated with Persistently Higher Direct Health Care Costs in Crohn's Disease: A Population-Based Study.
    Dig Dis Sci. 2023 Oct 5. doi: 10.1007/s10620-023-08096.
    PubMed         Abstract available

  10. PEREYRA L, Gomez EE, Gonzalez RA, Smolarczuk A, et al
    Impact of an Educational Mobile App on Inflammatory Bowel Disease Colonoscopy Report Quality.
    Dig Dis Sci. 2023 Oct 5. doi: 10.1007/s10620-023-08120.
    PubMed         Abstract available

  11. DUNLEAVY KA, Raffals LE, Camilleri M
    Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics.
    Dig Dis Sci. 2023 Sep 29. doi: 10.1007/s10620-023-08122.
    PubMed         Abstract available


    Gastroenterol Hepatol

  12. FORTUNY M, Gutierrez-Rios L, Vayreda E, Manosa M, et al
    Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab.
    Gastroenterol Hepatol. 2023;46:629-630.
    PubMed        

  13. LAO DOMINGUEZ FA, Fobelo Lozano MJ, Gutierrez Pizarraya A, Castro Fernandez M, et al
    Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023;46:631-632.
    PubMed        


    Inflamm Bowel Dis

  14. RAO V, Cockburn E, Segal JP
    Is Ulcerative Colitis Really Ever "Cleared?".
    Inflamm Bowel Dis. 2023 Oct 5:izad234. doi: 10.1093.
    PubMed        

  15. LAHEIJ RLH, van Knippenberg YMW, Heil ALJ, Mannaerts BJW, et al
    The Efficacy of an Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in Patients With Inflammatory Bowel Disease in Remission With Immunomodulators and/or Biological Agents: A Randomized, Double-Blind, Placebo-Controlled Clini
    Inflamm Bowel Dis. 2023 Oct 4:izad216. doi: 10.1093.
    PubMed         Abstract available

  16. BISLENGHI G, Van Den Bossch J, Fieuws S, Wolthuis A, et al
    Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric Study.
    Inflamm Bowel Dis. 2023 Oct 4:izad227. doi: 10.1093.
    PubMed         Abstract available

  17. TYRODE G, Lakkis Z, Vernerey D, Falcoz A, et al
    KONO-S Anastomosis Is Not Superior to Conventional Anastomosis for the Reduction of Postoperative Endoscopic Recurrence in Crohn's Disease.
    Inflamm Bowel Dis. 2023 Sep 30:izad214. doi: 10.1093.
    PubMed         Abstract available

  18. LEE YJ, Li D, Mujukian A, Debbas P, et al
    Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Sep 29:izad198. doi: 10.1093.
    PubMed        

  19. YANG W, Cong Y
    Exploring Colitis through Dynamic T Cell Adoptive Transfer Models.
    Inflamm Bowel Dis. 2023;29:1673-1680.
    PubMed         Abstract available

  20. YIN Y, Wan J, Yu J, Wu K, et al
    Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology.
    Inflamm Bowel Dis. 2023;29:1648-1657.
    PubMed         Abstract available

  21. WEIDINGER C, Siegmund B
    Deciphering Cellular Networks in Creeping Fat.
    Inflamm Bowel Dis. 2023;29:1670-1672.
    PubMed        


    J Crohns Colitis

  22. FERRANTE M, Irving PM, Abreu MT, Axler J, et al
    Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
    J Crohns Colitis. 2023 Oct 5:jjad168. doi: 10.1093.
    PubMed         Abstract available

  23. ATREYA R, Kuhbacher T, Waldner MJ, Hirschmann S, et al
    Submucosal injection of the RNA oligonucleotide GUT-1 in active ulcerative colitis patients: A randomized, double-blind, placebo-controlled phase 2a induction trial.
    J Crohns Colitis. 2023 Sep 30:jjad162. doi: 10.1093.
    PubMed         Abstract available

  24. BAI BYH, Reppell M, Smaoui N, Waring JF, et al
    Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn's disease patients.
    J Crohns Colitis. 2023 Sep 30:jjad166. doi: 10.1093.
    PubMed         Abstract available


    Mediators Inflamm

  25. LI XH, Liu L, Wu WZ
    Trans-Anethole Alleviates DSS-Induced Ulcerative Colitis by Remodeling the Intestinal Flora to Regulate Immunity and Bile Acid Metabolism.
    Mediators Inflamm. 2023;2023:4188510.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.